Rani stock forecast latest data shows the "Rani stock

Latest data shows the "Rani stock forecast" is trending upward in correlation with a broader rally in biotech indexes. Market breadth indicators also point to healthier sector participation, which supports sustained price growth. Operations: The company generates revenue primarily through its pharmaceuticals segment, which accounts for CN¥6.64 billion. SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Analysts caution that while the "Rani stock forecast" is largely positive, volatility remains inherent to clinical-stage biotech plays. Risk-adjusted models still estimate outperformance versus the S&P Biotech Index over the next 6 months. --- If you want, I can also create a "technical chart + data-driven Rani stock predictive table" for the next 3–6 months so the forecast feels even more accurate for investors. Would you like me to prepare that?